Triple-Drug cocktail shows promise for tough bile duct cancer
NCT ID NCT05052099
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of three drugs—chemotherapy (mFOLFOX6), an immunotherapy (atezolizumab), and a targeted therapy (bevacizumab)—in 20 people with advanced bile duct cancer who had already received one prior treatment. The goal was to see if the combination could shrink tumors or control the disease. The drugs were given every two weeks until the cancer worsened, side effects became too severe, or the patient chose to stop.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
A combination of chemotherapy (mFOLFOX6), an immunotherapy drug (atezolizumab), and a targeted therapy (bevacizumab), all given by IV.
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced bile duct cancer who have already tried one line of therapy.
What could go wrong
This was a small, early-phase study (20 people) with no comparison group. The combination may cause significant side effects, and it is not yet known if it works better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clínica Universidad de Navarra
Pamplona, 31008, Spain
-
Universitätsklinikum Essen
Essen, North Rhine-Westphalia, 45147, Germany